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Abstract 
Objective: Increased levels of circulating tissue factor (TF) in the form of microparticles 
increase the risk of thrombosis. However, any direct influence of microparticle-associated 
TF on vascular endothelial cell proliferation is not known. In this study, the influence of 
recombinant and microparticle-associated TF on endothelial cell proliferation and MAPK 
signalling mechanisms was examined. Methods and Results: Incubation of human coronary 
artery endothelial cells (HCAEC) with lipidated recombinant full length TF, or TF-
containing microparticles (50-200 pmol/L TF) increased the rate of cell proliferation and 
induced phosphorylation of ERK1 in a TF-dependent manner. Inhibition of ERK1/2 using 
PD98059 or ERK1/2 anti-sense oligonucleotides, or inhibition of JNK reduced recombinant 
TF-mediated cell proliferation. PD98059 also reduced cell proliferation in response to TF-
containing microparticles. Inclusion of FVIIa (5 nmol/L) and FXa (10 nmol/L) or pre-
incubation of cells with an inhibitory anti-FVIIa antibody had no additional influence on TF-
mediated cell proliferation. However, pre-incubation of exogenous TF with a β1-integrin 
peptide (amino acids 579-799) reduced TF-mediated proliferation. Conclusions: High 
concentrations of recombinant or microparticle-associated TF stimulate endothelial cell 
proliferation through activation of the ERK1/2 pathway, mediated through a novel 
mechanism requiring the interaction of exogenous TF with cell surface β1-integrin and 
independent of FVIIa. 
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Condensed Abstract 
Incubation of endothelial cells with lipidated recombinant tissue factor or tissue factor-
containing microparticles resulted in increases in cell proliferation in vitro. This was 
dependent on the activation of the ERK1/2 pathway and involved the interaction between 
tissue factor and β1-integrin but did not require FVIIa.  
 
In addition to its role in haemostasis, tissue factor (TF) has non-haemostatic functions which 
arise from its ability to activate various intracellular signalling pathways [1-3], leading to 
changes in cell proliferation [4], cell migration [5], and gene expression [6]. It has previously 
been shown that TF:FVIIa-mediated activation of the ERK1/2 pathway results in smooth 
muscle cell proliferation [4]. Furthermore, it has been shown that incubation of endothelial 
cells with recombinant TF alone induces cellular proliferation, together with an associated 
upregulation of cyclin D1 expression in these cells [7]. Recently, a number of reports have 
demonstrated the ability of TF to interact with cell surface integrins [8-11], resulting in 
diverse cellular outcomes including the activation of cell signalling pathways, cell migration 
and capillary tube formation [8,9,11]. The binding of cell surface TF to β1, α3 and α6-
integrins on endothelial cells was shown to require FVIIa [9], whereas binding of 
alternatively spliced TF (asTF) to αvβ3 and α6β1-integrins was shown to be independent of 
FVIIa [11]. We have previously demonstrated the interaction of lipidated recombinant TF 
with the β1-integrin subunit and shown that this was independent of FVIIa [10]. However, 
the mechanism by which TF interacts with integrins remains unclear.  
TF can be released from cells in the form of microparticles, which constitute a proportion of 
circulating TF [12]. TF-containing microparticles may be released from various cells 
including monocytes/macrophages [13], endothelial cells [13] and smooth muscle cells [14]. 
These microparticles are highly procoagulant due to the presence of TF and 
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phosphatidylserine, and elevations in the level of circulating microparticle-associated TF 
have been linked to an increased risk of thrombosis in a number of vascular conditions [15-
18]. Furthermore, it has been demonstrated that microparticles can transfer TF between 
different cell types [19,20]. It has previously been shown that the incubation of human 
umbilical vein endothelial cells with exogenous recombinant TF results in the induction of a 
number of cell signalling pathways [21], despite the lack of PAR2 in these cells. Moreover, 
it was demonstrated that this form of TF interacts with the cell surface [7,10,21]. This study 
is an attempt to further elucidate the mechanisms by which exogenous TF induces 
endothelial cell proliferation. Throughout this investigation, two forms of “exogenous” TF; 
lipidated recombinant TF and TF-containing cell-derived microparticles, have been used at 
concentrations of TF corresponding to those found in healthy individuals (5-10 pmol/L) or in 
plasma of patients with cardiovascular disease (50-200 pmol/L) [22,23]. We provide 
evidence that both recombinant TF and microparticle-associated TF increase endothelial cell 
proliferation through a mechanism that involves ERK1/2 activation and requires cell surface 
β1-integrin, but is independent of FVIIa. 
 
Methods 
Materials 
Polyclonal anti-human TF antibody, lipidated recombinant full length TF, non-lipidated 
recombinant TF, recombinant FVIIa and recombinant FXa were purchased from American 
Diagnostica Inc. The recombinant β1-integrin peptide (amino acids 579-799) was obtained 
from ProSpec-Tany TechnoGene Ltd. Please see http://atvb.ahajournals.org for a complete 
list of reagents. 
Cell culture 
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Human coronary artery endothelial cells (HCAEC) (PromoCell) were cultured under 5% 
CO2 at 37ºC in endothelial cell growth medium (PromoCell) containing 5% (v/v) foetal calf 
serum and growth supplements. For serum-free experiments, the FCS concentration was 
gradually reduced, and finally the cells washed with PBS and placed in serum-free medium 
supplemented with EGF (10 ng/ml) and bFGF (20 ng/ml).  
Proliferation and apoptosis assays 
Cell proliferation was measured using an MTS-based assay and cell numbers confirmed by 
staining with crystal violet. Apoptosis was measured using the DeadEnd Fluorimetric 
TUNEL assay (Promega). Please see http://atvb.ahajournals.org for further details. 
SDS-PAGE and western blot analysis 
Whole cell lysates (10 μg protein) were separated by SDS-PAGE and analysed by western 
blot using antibodies against total or phosphorylated forms of ERK1/2, JNK1/2 or p38. 
Please see http://atvb.ahajournals.org for further details.  
Microparticle preparation 
Cell-derived microparticles were prepared by ultracentrifugation as described before [10]. 
The concentrations of microparticles were determined using the Zymuphen microparticle 
determination kit (Hyphen BioMed). TF antigen and activity levels were measured using a 
TF-ELISA kit (Affinity Biologicals) and two-stage chromogenic assay respectively [24,25]. 
Please see http://atvb.ahajournals.org for further details. 
ERK1/2 inhibition using anti-sense oligodeoxynucleotides 
Sequences for ERK1/2 anti-sense (5’-GCCGCCGCCGCCGCCAT-3’), sense (5’-
ATGGCGGCGGCGGCGGC-3’) and scrambled (5’-CGCGCGCTCGCGCACCC-3’) 
phosphorothioate-modified oligodeoxynucleotides (ODN) were according to a published 
procedure [26]. The scrambled ODN was synthesised with a 3’-FITC group to allow 
transfection efficiency to be determined by flow cytometry. HCAEC (12.5×104) were 
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adapted to OptiMEM reduced serum medium and transfected with the ERK1/2 ODN (0.1 
μmol/L) using Lipofectin according to the manufacturers instructions. The cells were 
incubated at 37ºC for 5 h and then placed in medium containing 1% (v/v) FCS. The cells 
were incubated at 37ºC for 48 h, adapted to serum-free medium and used in experiments.  
Statistical analysis 
Data are expressed as mean±SEM. The data were analysed using the statistical package for 
the social sciences (SPSS). Significance was determined using one-way ANOVA and values 
of p<0.05 were considered to be significant. 
 
Results 
Lipidated recombinant TF and microparticle-TF induce proliferation in HCAEC  
To ensure consistency between the microparticle preparations the concentration of TF 
antigen and levels of TF activity of the microparticles isolated from TF-transfected and non-
transfected ECV304 and HCAEC cells were determined prior to use (Supplemental Table I). 
Moreover, the concentration of total released microparticles was consistent between different 
preparations (0.32±0.06 nmol/L) and the phosphatidylserine:phosphatidylcholine (PS:PC) 
ratio was consistently 33±2.4:67±2.4 as determined by thin layer chromatography. The ratio 
of microparticle concentration to number of cells was 1.5±0.2 pmol microparticles per 106 
cells, and the total concentrations of microparticles from TF-transfected and non-transfected 
cells were similar. Furthermore, the absence of the exosome marker Tsg101 in the 
microparticle preparations from both ECV304 and HCAEC suggests that the microparticles 
were ectosomes derived from the cell surface rather than exosomes (Supplemental Figure I-
A) [27]. Incubation of HCAEC with TF-containing microparticles (200 pmol/L) resulted in 
rapid depletion of TF from the culture media (Supplemental Figure I-B), indicating 
microparticle uptake by the cells. Incubation of HCAEC with high concentrations of 
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lipidated recombinant TF (50-200 pmol/L) resulted in increases in cell proliferation of up to 
82% above that of the untreated control (Fig 1A). Addition of ECV304-derived 
microparticles (Fig 1B) or HCAEC-derived microparticles (Fig 1C) containing 100-200 
pmol/L of TF resulted in increases in cell proliferation of up to 37%, whereas corresponding 
concentrations of control-microparticles had little influence. Pre-incubation of recombinant 
TF or TF-microparticles (100 pmol/L) with an anti-TF polyclonal antibody (100 μg/ml) 
reduced cell proliferation in response to all forms of exogenous TF. In contrast, non-
lipidated recombinant TF, or a mixture of PS:PC (30:70) alone had no measurable influence 
on cell proliferation (Supplemental Figure II-A). TF-containing microparticles (100 pmol/L 
TF) isolated from the plasma of patients with cardiovascular disease (Innovative Research 
Inc.) also induced proliferation of endothelial cells which was reduced by differing amounts 
in the different samples by pre-incubation of the microparticles with an anti-TF polyclonal 
antibody (Supplemental Figure II-B). Incubation of HCAEC with lipidated recombinant TF 
(100 pmol/L) or cell-derived microparticles did not induce cellular apoptosis (Supplemental 
Figure III). 
 
Lipidated recombinant TF and microparticle-TF induce activation of MAPK cell 
signalling pathways 
To elucidate the signalling pathways involved in the induction of endothelial cell 
proliferation by exogenous TF, the activation of the mitogen activated protein kinase 
(MAPK) pathways was examined. Incubation of HCAEC with lipidated recombinant TF 
(100 pmol/L) resulted in ERK1 phosphorylation, which peaked at 30 min post-treatment (Fig 
2A). Furthermore, incubation of cells with lipidated recombinant TF (100 pmol/L) resulted 
in JNK1 phosphorylation, which peaked at the later time point of 50 min (Fig 2B). No 
phosphorylation of p38 was detected in any of the samples (data not shown). HCAEC-
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derived microparticles containing 200 pmol/L of TF induced ERK1 phosphorylation, 
whereas control microparticles at similar microparticle densities had little influence (Fig 2C). 
 
Inhibition of ERK1/2 suppresses lipidated recombinant TF and microparticle-TF-
induced cell proliferation 
Inhibition of ERK1/2 phosphorylation prior to incubation of cells with lipidated recombinant 
TF (100 pmol/L), was achieved by pre-incubation of HCAEC with the MEK inhibitor 
PD98059 (15-50 μmol/L) for 30 min, and inhibition of the phosphorylation of the JNK 
substrate c-Jun was achieved by pre-incubation with SP600125 (60 nmol/L) for 30 min 
(Supplemental Figure IV-A). Incubation of HCAEC with PD98059 (15-50 μmol/L) 
completely inhibited cell proliferation in response to lipidated recombinant TF (100 pmol/L) 
(Fig 3A), while inclusion of SP600125 (20-60 nmol/L) showed a dose-dependent decrease in 
cell proliferation, inhibiting cell proliferation at 60 nmol/L compared to cells treated with TF 
(100 pmol/L) alone (Fig 3B). Pre-incubation of HCAEC with PD98059 (50 µmol/L) also 
reduced cell proliferation in response to HCAEC-derived microparticles containing TF (200 
pmol/L), while inclusion of SP600125 (60 nmol/L) had a marginal effect (Supplemental 
Figure IVB). Furthermore, inclusion of PD98059 alone (50 µmol/L) modestly reduced cell 
numbers compared to the untreated sample, which was attributed to a small increase in 
cellular apoptosis observable in the presence of high concentrations of this inhibitor 
(Supplemental Figure III). 
 
To confirm the data obtained using PD98059, HCAEC were transfected with ERK1/2 anti-
sense ODN (optimised to 0.1 μmol/L, Supplemental Figure V-A) to inhibit the expression of 
ERK1/2. Optimal suppression of ERK1/2 expression following transfection of HCAEC with 
ERK1/2 anti-sense ODN (0.1 μmol/L) was achieved at 48 h compared to non-transfected 
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cells, while JNK expression remained unaffected (Fig 3C). Furthermore, sense and 
scrambled ODN (0.1 μmol/L) had no effect on ERK1/2 expression (Supplemental Figure V-
B). Transfection efficiency of the cells following transfection of HCAEC with the 3’-FITC-
labelled scrambled ODN (0.1 μmol/L) was determined to be 85% using flow cytometry (data 
not shown). Transfection of HCAEC with ERK1/2 anti-sense ODN prevented the induction 
of cell proliferation in response to lipidated recombinant TF (100 pmol/L) (Fig 3D). In 
contrast, transfection of cells with ERK1/2 sense ODN had no measurable influence on TF-
mediated cell proliferation. 
 
The induction of HCAEC proliferation by recombinant TF and microparticle-TF does 
not require FVIIa  
Examination of HCAEC revealed no detectable surface TF expression or activity as 
determined by flow cytometry and the two-stage chromogenic assay respectively (data not 
shown). In addition, the expression of PAR1 and PAR2 in HCAEC was confirmed using 
RT-PCR (Supplemental Figure VI-A). Incubation of HCAEC with recombinant FVIIa (5 
nmol/L) and FXa (10 nmol/L) together with lipidated recombinant TF (100 pmol/L) had no 
additional influence on TF-mediated proliferation (Fig 4A). The enzymatic activities of 
recombinant FVIIa and FXa were confirmed using chromogenic substrates. Furthermore, 
pre-incubation of cells with an inhibitory anti-FVIIa antibody (30 μg/ml) (Fig 4A), or the 
inhibitory anti-PAR2 antibody SAM11 (25 μg/ml) (Supplemental Figure VI-B) did not 
reduce TF-mediated cell proliferation. The addition of recombinant FVIIa (5 nmol/L) alone 
or recombinant FXa (10 nmol/L) alone had no effect on cell proliferation (Fig 4A). Pre-
incubation of TF-containing microparticles with an inhibitory anti-FVIIa antibody also did 
not reduce cell proliferation in response to TF-containing microparticles (Fig 4B). These 
results were mirrored in ERK1 phosphorylation, since the incubation of HCAEC or 
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HCAEC-derived microparticles with the anti-FVIIa antibody did not reduce the level of 
ERK1 phosphorylation in response to either lipidated recombinant TF (Fig 4C), or 
microparticle-associated TF (Fig 4D). 
 
The induction of HCAEC proliferation by recombinant TF and microparticle-TF 
involves an interaction with β1-integrin 
Since TF has been shown to interact with integrins, the possibility that exogenous TF 
activates signalling through integrins was examined. The expression of β1-integrin and β3-
integrin on HCAEC was examined by flow cytometry, and HCAEC were found to express 
high levels of β1-integrin (90%) and lower levels of β3-integrin (32%) (data not shown). A 
peptide corresponding to amino acids 579-799 of β1-integrin was used to competitively 
inhibit the binding of exogenous TF to cell surface β1-integrin. Pre-incubation of lipidated 
recombinant TF (100 pmol/L) with the β1-integrin peptide (0.02-1 nmol/L) reduced TF-
mediated cell proliferation in a dose-dependent manner (Fig 4E). Concurrent with the 
reduced rate of cell proliferation, incubation of HCAEC with recombinant TF (100 pmol/L) 
pre-incubated with the β1-integrin peptide (1 nmol/L) reduced TF-mediated ERK1 
phosphorylation (Fig 4C), and a similar result was observed with TF-containing 
microparticles (200 pmol/L TF) (Fig 4D). An inhibitory anti-α3-integrin antibody also 
reduced recombinant TF-mediated HCAEC proliferation, whereas blocking β3-integrin or 
α6-integrin had no significant influence on recombinant TF-mediated increases in cell 
proliferation (Supplemental Figure VI-C). In addition, ERK1 phosphorylation in response to 
lipidated recombinant TF (100 pmol/L) was unaltered by pre-incubation of HCAEC with 
antibodies against β3-integrin, α3-integrin or α6-integrin (data not shown). The β1-integrin 
peptide (1 nmol/L) also significantly reduced cell proliferation (Fig 4B) and ERK1 
phosphorylation (Fig 4D) in response to TF-containing microparticles derived from HCAEC. 
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Pre-incubation of the β1-integrin peptide (1 nmol/L) with plasma-derived microparticles 
from patients with cardiovascular disease reduced cell proliferation in response to the 
microparticles in two of the samples (Supplemental Figure II-B). 
 
Influence of TF-containing microparticles from other vascular and blood cells on 
HCAEC proliferation 
Microparticles were isolated from activated THP-1 cells (monocytes), isolated peripheral 
blood mononuclear cells and human coronary artery smooth muscle cells. TF-containing 
microparticles (100 pmol/L TF) from these cells induced HCAEC proliferation to a similar 
extent as HCAEC-derived TF-containing microparticles, and was partly reduced by pre-
incubation of the microparticles with an anti-TF antibody (Supplemental Figure VII). 
 
Discussion 
Throughout this study, lipidated recombinant full-length TF was used in order to eliminate 
the influence of other proteins. In addition, cell-derived microparticles from primary 
endothelial cells and patient plasma-derived microparticles were used as a model of TF-
containing microparticles. TF-containing microparticles from the ECV304 cell line were also 
used in initial experiments (Fig 1B), and showed a similar pattern of inducing cell 
proliferation compared to microparticles derived from primary endothelial cells (Fig 1C), 
which were used thereafter. 
 
In this investigation both lipidated recombinant TF and TF-containing microparticles 
induced proliferation in coronary artery endothelial cells through activation of the ERK1/2 
pathway. A previous study has demonstrated that TF:FVIIa activation of the ERK1/2 
pathway is capable of inducing proliferation in smooth muscle cells [4], while our studies 
 12 
have shown that recombinant TF induces the proliferation of human umbilical vein 
endothelial cells (HUVEC) [7], as well as the activation of various cell signalling pathways 
[21]. In an extension to these studies, here we have shown the ability of microparticle-
associated TF and recombinant TF to induce signalling in endothelial cells and the data 
presented further supports the role of “exogenous” TF in promoting endothelial cell 
proliferation. Lipidated recombinant TF showed a greater ability to induce cell proliferation 
than the same concentrations of TF in cell-derived microparticles. This may be due to a 
proportion of the TF in the microparticles already being associated with integrins, or the 
presence of other proteins within the microparticles that may modulate these processes. 
Furthermore, the rate of cell proliferation varied between the different patient plasma-
derived microparticle samples, even though the TF concentration was the same, which may 
be explained by the heterogeneous nature of these microparticles. In addition, TF-containing 
microparticles isolated from other vascular and blood cells (THP-1 cells, isolated PBMC and 
HCASMC) induced proliferation in HCAEC, which was reduced by pre-incubation of the 
microparticles with anti-TF antibody, further supporting the role of TF in the induction of 
endothelial cell proliferation. In contrast, non-lipidated recombinant TF did not induce cell 
proliferation (Supplemental Fig 2A), indicating the requirement for exogenous TF to be in 
phospholipids. It is known that TF may be transferred between cell types by microparticles 
[19,20]. Furthermore, lipidated recombinant TF has been shown to be incorporated into the 
cell membrane [7,10]. It is therefore likely that the phospholipid component assists the 
fusion of microparticles with the cell membrane, resulting in the incorporation of TF into the 
cell membrane. The uptake of microparticles by HUVEC has previously been demonstrated 
[27]. Moreover, the rapid depletion of TF from the media (Supplemental Figure I-B) 
suggests uptake of TF-containing microparticles by HCAEC. However, a role for the ligand-
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mediated interaction of TF within microparticles and cell surface integrins in incorporating 
TF into the cell membrane cannot be ruled out. 
 
Although HCAEC were found to express PAR2, the ability of lipidated recombinant TF and 
microparticle-associated TF to induce cell proliferation did not require FVIIa. Furthermore, 
inclusion of an inhibitory PAR2 antibody did not prevent TF-mediated cell proliferation. 
Together these data indicate that exogenous TF is capable of inducing cell proliferation 
through a protease-independent mechanism. It has been reported that endothelial cells 
possess a cell-surface ligand for binding to TF [28]. More recent studies have shown that cell 
surface TF can interact with α3β1 and α6β1-integrins on endothelial cells [9]. Additionally, 
it has been shown that in epithelial cells and HUVEC, the interaction between cell surface 
TF and β1-integrin is enhanced by the presence of FVIIa, independently of FVIIa activity 
and PAR2 signalling, whereas in cancer cells the interaction between cellular TF and 
integrins is constitutive [9]. A recent study has also shown that asTF can interact with αvβ3 
and α6β1-integrins on HUVEC or an endothelial cell line, resulting in endothelial cell 
migration and capillary tube formation by a FVIIa-independent mechanism [11]. These 
reports further support our findings that TF can interact with integrins independently of 
FVIIa. In fact, we have previously shown that recombinant TF binds to the surface of breast 
cancer cells through direct binding to the β1-integrin subunit, and that this interaction was 
reduced by pre-incubation of cells with a polyclonal antibody directed against amino acids 
579-799 of β1-integrin [10]. Therefore, in this study a recombinant β1-integrin peptide 
corresponding to amino acids 579-799 of β1-integrin was used to competitively inhibit the 
binding of exogenous TF to cell surface β1-integrin. This β1-integrin peptide corresponds to 
the C-terminal of β1-integrin and includes the fourth EGF domain and βTD domain of the 
extracellular domain of β1-integrin, as well as the transmembrane and cytoplasmic domains 
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of β1-integrin [29]. The reduction in cell proliferation and ERK1 phosphorylation in 
response to both recombinant and microparticle-TF pre-incubated with this peptide suggests 
the presence of a novel binding site for exogenous TF within amino acids 579-799 of β1-
integrin, and that this interaction is required for TF-mediated proliferation of endothelial 
cells. Moreover, pre-incubation of patient plasma-derived microparticles with the β1-integrin 
peptide reduced cell proliferation to differing extents in the three patient samples. As 
previously mentioned, these variations may be a result of the heterogeneous nature of these 
microparticles, which may also be responsible for different levels of β1-integrin within the 
patient-plasma microparticles. Furthermore, patient-plasma microparticles are likely to be 
derived from other cell types in addition to endothelial cells such as macrophages, platelets 
and smooth muscle cells [13,14], and therefore contain different combinations of integrin 
subunits with which TF may interact. In addition, endothelial cell proliferation and ERK1 
phosphorylation in response to exogenous TF did not require β3-integrin or α6-integrin, 
whereas α3-integrin was partially involved in cell proliferation. In contrast to our data using 
recombinant full length TF or microparticle-associated TF, it has been shown that asTF is 
not capable of inducing proliferation in endothelial cells and does not interact with α3β1-
integrin [11]. However, the interaction of asTF with αvβ3 and α6β1-integrins has been 
shown to induce cell migration and tube formation respectively [11]. These differences may 
be due to the structure of asTF, since asTF lacks the cytoplasmic and transmembrane 
domains as well as part of the extracellular domain of full length TF [30], and therefore may 
interact with integrins in a different conformation [11] and have different cellular outcomes 
compared to full length exogenous TF. Furthermore, both asTF [11] and exogenous TF 
[7,24] have been shown to induce capillary tube formation. Since endothelial cell 
proliferation is essential for angiogenesis, it would be interesting to examine the influence of 
microparticle-associated TF on angiogenesis in coronary artery endothelial cells. In 
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conclusion, the binding of full length “exogenous” TF to β1-integrin provides a potentially 
novel mechanism for FVIIa-independent induction of endothelial cell proliferation by 
recombinant or microparticle-associated TF.  
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Figure 1. Recombinant and microparticle-TF induce proliferation in HCAEC. HCAEC were 
incubated with either lipidated recombinant TF (0-200 pmol/L) (n=8) (A), or microparticles 
(MP) derived from TF-transfected or non-transfected ECV304 cells (n=6) (B), or HCAEC 
(n=3) (C). Additional samples (100 pmol/L TF) were pre-incubated with an anti-human TF 
antibody (100 μg/ml) and added as above. HCAEC were incubated for 24 h following which 
cell proliferation was measured using the MTS-based assay and cell numbers confirmed by 
staining with crystal violet. *=p<0.05 vs. untreated control. #=p<0.05 vs. 100 pmol/L TF. 
 
Figure 2. Recombinant and microparticle-TF induce MAPK activation. HCAEC were 
incubated with recombinant TF (100 pmol/L) for 0-90 min and phosphorylation of ERK1/2 
(A) and JNK (B) analysed (n=3). C) HCAEC were incubated with microparticles derived 
from TF-transfected HCAEC at 50-200 pmol/L TF, or from non-transfected cells at 
equivalent microparticle densities. Additional samples (100 pmol/L TF) were pre-incubated 
with an anti-TF polyclonal antibody (100 μg/ml) and ERK1/2 phosphorylation analysed at 
30 min (n=3). *=p<0.05 vs. untreated control. Presented micrographs are representative of 
three independent experiments.  
 
Figure 3. Inhibition of ERK1/2 prevents recombinant and microparticle TF-mediated cell 
proliferation. HCAEC were pre-treated (30 min) with ERK1/2 inhibitor PD98059 (15-50 
μmol/L) (A) or JNK inhibitor SP600125 (20-60 nmol/L) (B) and recombinant TF (100 
pmol/L) added. Cells were incubated with TF and the inhibitors for 24 h following which 
cell proliferation was measured (n=6). *=p<0.05 vs. untreated control. #=p<0.05 vs. TF 
alone. C) The expression of ERK1/2, JNK and GAPDH in HCAEC was examined at 24, 48 
and 72 h post-transfection with anti-sense ERK1/2 ODN (0.1 μmol/L). D) HCAEC 
(12.5×104) were transfected with anti-sense (AS), sense (S) and scrambled (Scr) ERK1/2 
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ODN (0.1 μmol/L) for 48 h. Cells were then incubated with recombinant TF (100 pmol/L) 
and cell proliferation measured following a further 24 h incubation (n=4). *=p<0.05 vs. S. 
 
Figure 4. β1-integrin is involved in TF-mediated HCAEC proliferation. A) HCAEC adapted 
to serum-free media were incubated with recombinant TF (100 pmol/L) together with 
combinations of FVIIa (5 nmol/L) and FXa (10 nmol/L), an inhibitory anti-FVIIa antibody 
(30 μg/ml), or FVIIa and FXa alone for 24 h and cell proliferation measured (n=3, *=p<0.05 
vs. untreated control). B) HCAEC were incubated with TF-containing microparticles (200 
pmol/L TF) previously pre-incubated with the β1-integrin peptide (1 nmol/L) or FVIIa 
antibody (30 μg/ml), and proliferation measured after 24 h (n=4, *=p<0.05 vs. untreated 
control, #=p<0.05 vs. TF-MP). HCAEC were incubated for 30 min with recombinant TF 
(100 pmol/L TF) (C) or TF-containing microparticles (200 pmol/L TF) (D) in the presence 
of the β1-integrin peptide (1 nmol/L) or anti-FVIIa antibody (30 μg/ml) and ERK1/2 
phosphorylation examined (n=3, *=p<0.05 vs. untreated control). E) Recombinant TF (100 
pmol/L) pre-incubated with the β1-integrin peptide (0.02-1 nmol/L) for 40 min was added to 
HCAEC for 24 h and cell proliferation measured (n=5, *=p<0.05 vs. TF). 
 
